Stomatitis paclitaxel

Paclitaxel -natural taxane inhibits depolymerization of tubulin in mitotic spindle apparatus -bone marrow suppression -nausea and vomiting—mild -mucocutaneous effects (mucositis, stomatitis, diarrhea) -hypersensitivity reactions -peripheral neuropathy -myalgias, arthralgias -mild vesicant... 

The efficacy and toxicity of Caelyx in combination with paclitaxel (Taxol) were investigated as a first-line therapy in 34 patients with advanced breast cancer in a multicentric phase II study [428], Paclitaxel at a dose of 175 mg/m2 and Caelyx (30 mg/m2) were administered intravenously every 3 weeks. It was shown that the response rates of the combination were over 70% while the median time to treatment failure was 45 weeks. No significant clinical cardiotoxicity was observed and the usual side effects (mucositis, stomatitis, hand-foot syndrome) were treated accordingly. 

DOXORUBICIN PACLITAXEL t risk of neutropenia, stomatitis and cardiomyopathy due to t plasma concentrations of doxorubicin t risk of neutropenia, stomatitis and cardiomyopathy due to t plasma concentrations of doxorubicin when paditaxel is given before doxorubicin Doxorubicin should be administered prior to paditaxel. The cumulative dose of doxorubicin should be limited to 360 mg/m2 when concurrently administered with paditaxel... 

Mucositis and stomatitis have been reported with paclitaxel. Mucositis is characterized by ulceration of the lips, pharynx, and oral cavity, occurring 3-7 days after paclitaxel treatment (1,13,14,17,24,26,29,33,36-38). Mucositis appears to be more common during treatment of acute leukemias rather than solid tumors, when doses above 390 mg/m are used (24). Severe mucositis occurred during second and third courses, suggesting a cumulative effect, and was more severe if treatment was given at 15 days or less after previous courses. Patients... 

---